Citations

Clear

3942 citation(s) found for "To, Van".

Scapholunate Ligament Internal Brace 360 Tenodesis (SLITT) Procedure: A Biomechanical Study
Greene, Ryan M. , Denbeigh, Janet M. , Wijnen, André J. van , Denbeigh, Janet, van Wijnen, Andre, van Wijnen, Andre J , Kakar, Sanjeev

Mayo Clinic

Journal of Wrist Surgery | September 18, 2018 | Volume: 08 | Issue: 03 | Pages: 250-254

10.1055/s-0038-1670682 | PMID 31192049 Get It

Background Twelve paired fresh frozen cadaveric wrists were randomized to a 360-degree tenodesis repair group or the 360-degree tenodesis repair with an internal brace (suture tape) construct. Case Description The specimens were preloaded to 5 N and subsequently biomechanically loaded to failure, at a rate of 0.1 mm/s on a jig that allowed for axial load. The maximum load and mode of failure were recorded. Load to failure in the 360 tenodesis group with internal brace was 283.47 ± 100.25 N, compared with the 360 tenodesis group only, whose yield strength was 143.61 ± 90.54 N. The mode of failure within the internal brace construct was either through knot slippage, graft disruption, or bone separation from strength testing construct. The 360 tenodesis group tended to fail via graft slippage or graft rupture. Literature Review The management of scapholunate instability can be a difficult problem to treat. Traditionally, many of the surgical reconstructions have focused upon dorsal ligament reconstruction with Kirschner (K) wire fixation. This results in prolonged immobilization of the wrist with varied outcomes, in part due to the multiaxial instability that may persist due to concomitant volar ligament disruption. To address this instability, surgical techniques have been devised that address both the volar and dorsal ligament injuries. Clinical Relevance Scapholunate reconstruction with a 360-degree tenodesis and internal brace augmentation (SLITT procedure) provided superior biomechanical stability than tenodesis alone.
Elimination of Purkinje Fibers by Electroporation Reduces Ventricular Fibrillation Vulnerability
Livia, Christopher , Sugrue, Alan , Witt, Tyra A. , Polkinghorne, Murray , Maor, Elad , Behfar, Atta , Asirvatham, Samuel J. , Witt, Tyra, Polkinghorne, Murray D, Kapa, Suraj , Lehmann, Helge I, Behfar, Atta , Asirvatham, Samuel J , Livia, Christopher , Maor, Elad , Lehmann, H. Immo , DeSimone, Christopher V. , McLeod, Christopher J.

Mayo Clinic

Journal of the American Heart Association | September 16, 2018 | Volume: 7 | Issue: 15 | Pages: No page available

10.1161/jaha.118.009070 | PMID 30371233 Get It

Background The Purkinje network appears to play a pivotal role in the triggering as well as maintenance of ventricular fibrillation. Irreversible electroporation ( IRE ) using direct current has shown promise as a nonthermal ablation modality in the heart, but its ability to target and ablate the Purkinje tissue is undefined. Our aim was to investigate the potential for selective ablation of Purkinje/fascicular fibers using IRE . Methods and Results In an ex vivo Langendorff model of canine heart (n=8), direct current was delivered in a unipolar manner at various dosages from 750 to 2500 V, in 10 pulses with a 90‐μs duration at a frequency of 1 Hz. The window of ventricular fibrillation vulnerability was assessed before and after delivery of electroporation energy using a shock on T‐wave method. IRE consistently eradicated all Purkinje potentials at voltages between 750 and 2500 V (minimum field strength of 250–833 V/cm). The ventricular electrogram amplitude was only minimally reduced by ablation: 0.6±2.3 mV ( P =0.03). In 4 hearts after IRE delivery, ventricular fibrillation could not be reinduced. At baseline, the lower limit of vulnerability to ventricular fibrillation was 1.8±0.4 J, and the upper limit of vulnerability was 19.5±3.0 J. The window of vulnerability was 17.8±2.9 J. Delivery of electroporation energy significantly reduced the window of vulnerability to 5.7±2.9 J ( P =0.0003), with a postablation lower limit of vulnerability=7.3±2.63 J, and the upper limit of vulnerability=18.8±5.2 J. Conclusions Our study highlights that Purkinje tissue can be ablated with IRE without any evidence of underlying myocardial damage.
Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests
Hoogland, Jeroen , Wanrooij, Lennard L. van , Boel, Judith A., Goldman, Jennifer G. , Stebbins, Glenn T. , Dalrymple‐Alford, John C. , Junqué, Carme , Pedersen, Kenn Freddy , Mollenhauer, Brit , Zabetian, Cyrus P. , Eslinger, Paul J. , Lewis, Simon J.G. , Wu, Ruey‐Meei , Klein, Martin , Rodríguez‐Oroz, María , Cammisuli, Davide Maria , Biundo, Roberta , Bie, Rob M.A. de , Schmand, Ben , Tröster, Alexander I. , Burn, David J. , Filoteo, J. Vincent , Geurtsen, Gert J. , Disease”, on behalf of the IPMDS Study Group “Validation of Mild Cognitive Impairment in Parkinson, Goldman, Jennifer G , Dalrymple-Alford, John C , Lewis, Simon J G , Zabetian, Cyrus P , de Bie, Rob M A , Geurtsen, Gert J , Junque, Carme , Marras, Connie , Adler, Charles H. , Barone, Paolo , Litvan, Irene , Weintraub, Daniel , Disease”, on behalf of the IPMDS Study Group “Validation of Mild Cognitive Impairment in Parkinson, Wu, Ruey-Meei

Mayo Clinic

Movement Disorders | September 14, 2018 | Volume: 33 | Issue: 11 | Pages: 1750-1759

10.1002/mds.110 | PMID 30216541 Get It

AbstractBackground: Numerous neuropsychological tests and test versions are used in Parkinson's disease research, but their relative capacity to detect mild cognitive deficits and their comparability across studies are unknown. The objective of this study was to identify neuropsychological tests that consistently detect cognitive decline in PD across studies.Methods: Data from 30 normed neuropsychological tests across 20 international studies in up to 2908 nondemented PD patients were analyzed. A subset of 17 tests was administered to up to 1247 healthy controls. A 2‐step meta‐analytic approach using standardized scores compared performance in PD with normative data.Results: Pooled estimates of the differences between PD and site‐specific healthy controls identified significant cognitive deficits in PD patients on 14 test scores across 5 commonly assessed cognitive domains (attention or working memory, executive, language, memory, and visuospatial abilities), but healthy control performance was statistically above average on 7 of these tests. Analyses based on published norms only, as opposed to direct assessment of healthy controls, showed high between‐study variability that could not be accounted for and led to inconclusive results.Conclusions: Normed neuropsychological tests across multiple cognitive domains consistently detect cognitive deficits in PD when compared with site‐specific healthy control performance, but relative PD performance was significantly affected by the inclusion and type of healthy controls versus the use of published norms only. Additional research is needed to identify a cognitive battery that can be administered in multisite international studies and that is sensitive to cognitive decline, responsive to therapeutic interventions, and superior to individual cognitive tests. © 2018 International Parkinson and Movement Disorder Society
Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study
Griffith, David E. , Eagle, Gina , Thomson, Rachel , Aksamit, Timothy R. , Hasegawa, Naoki , Addrizzo‐Harris, Doreen , O’Donnell, Anne E., Marras, Theodore K. , Loebinger, Michael R. , Morgan, Lucy , Codecasa, Luigi Ruffo , Ruoss, Stephen J. , Yim, Jae‐Joon , Ringshausen, Felix C. , Wallace, Richard J. , Ingen, Jakko van , Coulter, Chris, Nezamis, James, Winthrop, Kevin , Haddad, Tarik , Addrizzo-Harris, Doreen , O'Donnell, Anne E , Morimoto, Kozo , Flume, Patrick A. , Hill, Adam T. , Field, Stephen K. , Philley, Julie V.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | September 14, 2018 | Volume: 198 | Issue: 12 | Pages: 1559-1569

10.1164/rccm.201807-1318oc | PMID 30216086 Get It

Abstract Rationale Improved therapeutic options are needed for patients with treatment-refractory nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex (MAC). Objectives To evaluate the efficacy and safety of daily amikacin liposome inhalation suspension (ALIS) added to standard guideline-based therapy (GBT) in patients with refractory MAC lung disease. Methods Adults with amikacin-susceptible MAC lung disease and MAC-positive sputum cultures despite at least 6 months of stable GBT were randomly assigned (2:1) to receive ALIS with GBT (ALIS + GBT) or GBT alone. Once-daily ALIS was supplied in single-use vials delivering 590 mg amikacin to the nebulizer. The primary endpoint was culture conversion, defined as three consecutive monthly MAC-negative sputum cultures by Month 6. Measurements and Main Results Enrolled patients (ALIS + GBT, n = 224; GBT-alone, n = 112) were a mean 64.7 years old and 69.3% female. Most had underlying bronchiectasis (62.5%), chronic obstructive pulmonary disease (14.3%), or both (11.9%). Culture conversion was achieved by 65 of 224 patients (29.0%) with ALIS + GBT and 10 of 112 (8.9%) with GBT alone (odds ratio, 4.22; 95% confidence interval, 2.08–8.57; P < 0.001). Patients in the ALIS + GBT arm versus GBT alone were more likely to achieve conversion (hazard ratio, 3.90; 95% confidence interval, 2.00–7.60). Respiratory adverse events (primarily dysphonia, cough, and dyspnea) were reported in 87.4% of patients receiving ALIS + GBT and 50.0% receiving GBT alone; serious treatment-emergent adverse events occurred in 20.2% and 17.9% of patients, respectively. Conclusions Addition of ALIS to GBT for treatment-refractory MAC lung disease achieved significantly greater culture conversion by Month 6 than GBT alone, with comparable rates of serious adverse events. Clinical trial registered with www.clinicaltrials.gov (NCT02344004).
Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy
Berkeley, Robert A., Steele, Lynette P., Mulder, Aat A. , Wollenberg, Diana J.M. van den , Kottke, Timothy, Thompson, Jill , Coffey, Matthew, Hoeben, Rob C. , Vile, Richard G. , Melcher, Alan , Ilett, Elizabeth J. , Kottke, Timothy J, Ilett, Elizabeth J , Melcher, Alan A

Mayo Clinic

Cancer Immunology Research | September 12, 2018 | Volume: 6 | Issue: 10 | Pages: 1161-1173

10.1158/2326-6066.cir-18-0309 | PMID 30209061 Get It

Abstract Immunotherapy is showing promise for otherwise incurable cancers. Oncolytic viruses (OVs), developed as direct cytotoxic agents, mediate their antitumor effects via activation of the immune system. However, OVs also stimulate antiviral immune responses, including the induction of OV-neutralizing antibodies. Current dogma suggests that the presence of preexisting antiviral neutralizing antibodies in patients, or their development during viral therapy, is a barrier to systemic OV delivery, rendering repeat systemic treatments ineffective. However, we have found that human monocytes loaded with preformed reovirus–antibody complexes, in which the reovirus is fully neutralized, deliver functional replicative reovirus to tumor cells, resulting in tumor cell infection and lysis. This delivery mechanism is mediated, at least in part, by antibody receptors (in particular FcγRIII) that mediate uptake and internalization of the reovirus/antibody complexes by the monocytes. This finding has implications for oncolytic virotherapy and for the design of clinical OV treatment strategies. Cancer Immunol Res; 6(10); 1161–73. ©2018 AACR.
A Call to Action for Optimizing the Electronic Health Record in the Parenteral Nutrition Workflow: Executive Summary
Vanek, Vincent W., Ayers, Phil , Kraft, Michael D. , Bouche, Jean M., Do, Van T., Durham, Charles W., Guenter, Peggi , Hoggle, Lindsey, Kent, Sue, Lin, Emily T., Molinar, L. Steven , Plogsted, Steven W., Poehls, Jessica M., Turner, Peggy, Way, Charles W. Van , Kraft, Michael , Van Way, Charles , Durham, Charles W.

Mayo Clinic

Nutrition in Clinical Practice | September 12, 2018 | Volume: 33 | Issue: 5 | Pages: 594-596

10.1002/ncp.10202 | PMID 30208264 Get It

AbstractParenteral nutrition (PN) is a complex therapeutic modality provided to neonates, children, and adults for various indications. Surveys have shown that current electronic health record (EHR) systems are in need of functionality enhancement for safe and optimal delivery of PN. This is a consensus statement from the American Society for Parenteral and Enteral Nutrition, the Academy of Nutrition and Dietetics, and the American Society of Health‐System Pharmacists outlining some of the key challenges to prescribing, order review/verification, compounding, and administration of PN using EHRs today and is a call to action for clinicians and vendors to optimize their EHRs regarding the PN build and workflow.
Mll‐COMPASS complexes mediate H3K4me3 enrichment and transcription of the osteoblast master gene Runx2/p57 in osteoblasts
Rojas, Adriana , Sepúlveda, Hugo , Henríquez, Berta, Aguilar, Rodrigo , Opazo, Tatiana , Nardocci, Gino , Bustos, Fernando J. , Lian, Jane B. , Stein, Janet L. , Stein, Gary S., Zundert, Brigitte van , Wijnen, André J. van , Allende, Miguel L. , Montecino, Martı́n , Bustos, Fernando , van Wijnen, Andre J

Mayo Clinic

Journal of Cellular Physiology | September 7, 2018 | Volume: 234 | Issue: 5 | Pages: 6244-6253

10.1002/jcp.27355 | PMID 30256410 Get It

Abstract Expression of Runx2/p57 is a hallmark of the osteoblast‐lineage identity. Although several regulators that control the expression of Runx2/p57 during osteoblast‐lineage commitment have been identified, the epigenetic mechanisms that sustain this expression in differentiated osteoblasts remain to be completely determined. Here, we assess epigenetic mechanisms associated with Runx2/p57 gene transcription in differentiating MC3T3 mouse osteoblasts. Our results show that an enrichment of activating histone marks at the Runx2/p57 P1 promoter is accompanied by the simultaneous interaction of Wdr5 and Utx proteins, both are components of COMPASS complexes. Knockdown of Wdr5 and Utx expression confirms the activating role of both proteins at the Runx2‐P1 promoter. Other chromatin modifiers that were previously described to regulate Runx2/p57 transcription in mesenchymal precursor cells (Ezh2, Prmt5, and Jarid1b proteins) were not found to contribute to Runx2/p57 transcription in full‐committed osteoblasts. We also determined the presence of additional components of COMPASS complexes at the Runx2/p57 promoter, evidencing that the Mll2/COMPASS‐ and Mll3/COMPASS‐like complexes bind to the P1 promoter in osteoblastic cells expressing Runx2/p57 to modulate the H3K4me1 to H3K4me3 transition.
Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028—A multicenter phase II study.
Tawbi, Hussein, Crowley, John, Tine, Brian Andrew Van, Hu, James , Schuetze, Scott M. , Attia, Steven , Priebat, Dennis A., Okuno, Scott H. , Riedel, Richard F. , Movva, Sujana , Baker, Laurence H. , Maki, Robert G. , Patel, Shreyaskumar , Investigators, for SARC028, Maki, Robert G , Riedel, Richard F , Burgess, Melissa , D'Angelo, Sandra P , Davis, Lara E. , Reed, Damon R. , Reinke, Denise K. , Investigators, for SARC028

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 11006-11006

10.1200/jco.2016.34.15_suppl.11006 Get It

Efficacy and safety of ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) by cytogenetic risk status in the global phase III Tourmaline-MM1 study.
Richardson, Paul G. , Palumbo, Antonio , Viterbo, Luísa, Nagler, Arnon , Yehuda, Dina Ben , Pour, Luděk, Langer, Christian , Pluta, Andrzej, Berg, Deborah, Velde, Helgi van de , Esseltine, Dixie-Lee, Bacco, Alessandra Di , Richardson, Paul Gerard Guy , Avet‐Loiseau, Hervé , Ganly, Peter S. , Miguel, Jesús F. San , Rajkumar, S. Vincent , Bahlis, Nizar Jacques , Masszi, Tamás , Lin, Jianchang , Esseltine, Dixie‐Lee, Moreau, Philippe

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8018-8018

10.1200/jco.2016.34.15_suppl.8018 Get It

Outcomes in refractory aggressive diffuse large b-cell lymphoma (DLBCL): Results from the international SCHOLAR-1 study.
Crump, Michael , Neelapu, Sattva S. , Neste, Éric Van Den, Ahmed, Mohamed , Zhu, Liting , Feng, Lei, Navale, Lynn, Wiezorek, Jeffrey S., Go, William Y., Gisselbrecht, Christian , Farooq, Umar , Kuruvilla, John , Link, Brian K. , Hay, Annette E. , Cerhan, James R. , Boussetta, Sami , Maurer, Matthew J.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7516-7516

10.1200/jco.2016.34.15_suppl.7516 Get It